438 related articles for article (PubMed ID: 17701536)
1. Conformal radiotherapy plus local hyperthermia in patients affected by locally advanced high risk prostate cancer: preliminary results of a prospective phase II study.
Maluta S; Dall'Oglio S; Romano M; Marciai N; Pioli F; Giri MG; Benecchi PL; Comunale L; Porcaro AB
Int J Hyperthermia; 2007 Aug; 23(5):451-6. PubMed ID: 17701536
[TBL] [Abstract][Full Text] [Related]
2. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
[TBL] [Abstract][Full Text] [Related]
3. Regional hyperthermia combined with radiotherapy for uterine cervical cancers: a multi-institutional prospective randomized trial of the international atomic energy agency.
Vasanthan A; Mitsumori M; Park JH; Zhi-Fan Z; Yu-Bin Z; Oliynychenko P; Tatsuzaki H; Tanaka Y; Hiraoka M
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):145-53. PubMed ID: 15629605
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.
Akakura K; Suzuki H; Ichikawa T; Fujimoto H; Maeda O; Usami M; Hirano D; Takimoto Y; Kamoto T; Ogawa O; Sumiyoshi Y; Shimazaki J; Kakizoe T;
Jpn J Clin Oncol; 2006 Dec; 36(12):789-93. PubMed ID: 17082219
[TBL] [Abstract][Full Text] [Related]
5. Treatment for intermediate and high-risk prostate cancer: controversial issues and the role of hyperthermia.
Maluta S; Dall'oglio S; Nadalini L
Int J Hyperthermia; 2010; 26(8):765-74. PubMed ID: 21043571
[TBL] [Abstract][Full Text] [Related]
6. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
7. Regional hyperthermia in conjunction with definitive radiotherapy against recurrent or locally advanced prostate cancer T3 pN0 M0.
Tilly W; Gellermann J; Graf R; Hildebrandt B; Weissbach L; Budach V; Felix R; Wust P
Strahlenther Onkol; 2005 Jan; 181(1):35-41. PubMed ID: 15660191
[TBL] [Abstract][Full Text] [Related]
8. Concurrent and adjuvant docetaxel with three-dimensional conformal radiation therapy plus androgen deprivation for high-risk prostate cancer: preliminary results of a multicentre phase II trial.
Bolla M; Hannoun-Levi JM; Ferrero JM; Maingon P; Buffet-Miny J; Bougnoux A; Bauer J; Descotes JL; Fourneret P; Jover F; Colonna M
Radiother Oncol; 2010 Nov; 97(2):312-7. PubMed ID: 20846737
[TBL] [Abstract][Full Text] [Related]
9. Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation.
Christie D; Denham J; Steigler A; Lamb D; Turner S; Mameghan H; Joseph D; Matthews J; Franklin I; Atkinson C; North J; Poulsen M; Spry NA; Tai KH; Wynne C; Duchesne G; Kovacev O; Francis L; Kramar A; D'Este C; Bill D
Radiother Oncol; 2005 Nov; 77(2):117-25. PubMed ID: 16271786
[TBL] [Abstract][Full Text] [Related]
10. Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy.
Valdagni R; Italia C; Montanaro P; Lanceni A; Lattuada P; Magnani T; Fiorino C; Nahum A
Radiother Oncol; 2005 Apr; 75(1):74-82. PubMed ID: 15878104
[TBL] [Abstract][Full Text] [Related]
11. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.
Kelly WK; Halabi S; Elfiky A; Ou SS; Bogart J; Zelefsky M; Small E;
Cancer; 2008 Dec; 113(11):3137-45. PubMed ID: 18989865
[TBL] [Abstract][Full Text] [Related]
12. Phase II feasibility study of high-dose radiotherapy for prostate cancer using proton boost therapy: first clinical trial of proton beam therapy for prostate cancer in Japan.
Nihei K; Ogino T; Ishikura S; Kawashima M; Nishimura H; Arahira S; Onozawa M
Jpn J Clin Oncol; 2005 Dec; 35(12):745-52. PubMed ID: 16314345
[TBL] [Abstract][Full Text] [Related]
13. 3D conformal radiation therapy for prostate cancer in elderly patients.
Geinitz H; Zimmermann FB; Thamm R; Schumertl A; Busch R; Molls M
Radiother Oncol; 2005 Jul; 76(1):27-34. PubMed ID: 15990188
[TBL] [Abstract][Full Text] [Related]
14. Technological advances in radiotherapy for the treatment of localised prostate cancer.
Mangar SA; Huddart RA; Parker CC; Dearnaley DP; Khoo VS; Horwich A
Eur J Cancer; 2005 Apr; 41(6):908-21. PubMed ID: 15808957
[TBL] [Abstract][Full Text] [Related]
15. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.
Rosenthal SA; Bae K; Pienta KJ; Sobczak ML; Asbell SO; Rajan R; Kerlin KJ; Michalski JM; Sandler HM;
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):672-8. PubMed ID: 18990504
[TBL] [Abstract][Full Text] [Related]
16. Dose escalation for prostate cancer using the three-dimensional conformal dynamic arc technique: analysis of 542 consecutive patients.
Jereczek-Fossa BA; Vavassori A; Fodor C; Santoro L; Zerini D; Cattani F; Garibaldi C; Cambria R; Fodor A; Boboc GI; Vitolo V; Ivaldi GB; Musi G; de Cobelli O; Orecchia R
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):784-94. PubMed ID: 18191332
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies.
Ben-Josef E; Normolle D; Ensminger WD; Walker S; Tatro D; Ten Haken RK; Knol J; Dawson LA; Pan C; Lawrence TS
J Clin Oncol; 2005 Dec; 23(34):8739-47. PubMed ID: 16314634
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study.
Ares C; Popowski Y; Pampallona S; Nouet P; Dipasquale G; Bieri S; Ozsoy O; Rouzaud M; Khan H; Miralbell R
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):656-63. PubMed ID: 19250768
[TBL] [Abstract][Full Text] [Related]
19. Need for high radiation dose (>or=70 gy) in early postoperative irradiation after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative patients.
Cozzarini C; Montorsi F; Fiorino C; Alongi F; Bolognesi A; Da Pozzo LF; Guazzoni G; Freschi M; Roscigno M; Scattoni V; Rigatti P; Di Muzio N
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):966-74. PubMed ID: 19619960
[TBL] [Abstract][Full Text] [Related]
20. Dynamic conformal arc radiotherapy with rectum hollow-out technique for localized prostate cancer.
Tomita N; Kodaira T; Tachibana H; Nakamura T; Tomoda T; Nakahara R; Inokuchi H; Hayashi N; Fuwa N
Radiother Oncol; 2009 Mar; 90(3):346-52. PubMed ID: 18950880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
